domingo, 27 de noviembre de 2016

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. - PubMed - NCBI

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. - PubMed - NCBI
 2016 Nov 5. pii: S0021-9150(16)31420-4. doi: 10.1016/j.atherosclerosis.2016.10.017. [Epub ahead of print]

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.

Abstract

This consensus statement addresses the current three main modalities of treatment of homozygous familial hypercholesterolaemia (HoFH): pharmacotherapy, lipoprotein (Lp) apheresis and liver transplantation. HoFH may cause very premature atheromatous arterial disease and death, despite treatment with Lp apheresis combined with statin, ezetimibe and bile acid sequestrants. Two new classes of drug, effective in lowering cholesterol in HoFH, are now licensed in the United Kingdom. Lomitapide is restricted to use in HoFH but, may cause fatty liver and is very expensive. PCSK9 inhibitors are quite effective in receptor defective HoFH, are safe and are less expensive. Lower treatment targets for lipid lowering in HoFH, in line with those for the general FH population, have been proposed to improve cardiovascular outcomes. HEART UK presents a strategy combining Lp apheresis with pharmacological treatment to achieve these targets in the United Kingdom (UK). Improved provision of Lp apheresis by use of existing infrastructure for extracorporeal treatments such as renal dialysis is promoted. The clinical management of adults and children with HoFH including advice on pregnancy and contraception are addressed. A premise of the HEART UK strategy is that the risk of early use of drug treatments beyond their licensed age restriction may be balanced against risks of liver transplantation or ineffective treatment in severely affected patients. This may be of interest beyond the UK.

KEYWORDS:

Consensus; HEART UK; Homozygous familial hypercholesterolaemia; Lipoprotein apheresis; Lomitapide; evolocumab, proprotein convertase subtilisin kexin type 9
PMID:
 
27839699
 
DOI:
 
10.1016/j.atherosclerosis.2016.10.017
[PubMed - as supplied by publisher] 
Free full text

Public Health Genomics Knowledge Base (v1.2)
Genomics & Health Impact Update banner with DNA in background


Last Updated: Nov 16, 2016
CDC Resources with and image of DNA
Seletced Insights & Reviews with various images of researchers in labortory environments
Epidemiology with an image of a crowd of people with a double helix
Translational Research with two images of people talking to a genetic counselor and an image of a hand with wrapped sequecing around it
Evidence Synthesis with an image of sequencing and a double helix
Practice & Implementation with images of people taking to a doctor and a nurse examining a child

Relevant Resources

No hay comentarios:

Publicar un comentario en la entrada